A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Study acronym: COMPASS-CD
StatusCompleted
PhasePhase 4
SponsorTakeda
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 243 to 241
  2. Trial completed Show 5 more changesShow less
    • Final enrollment: 243 participants (planned 200)
    • Primary and study completion dates changed from estimate of Sep 12, 2026 to Aug 27, 2026
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 6 of 8 entries
    • Site details revised at 3 of 44 sites
  3. Primary completion pushed from Jul 20, 2026 to Sep 12, 2026v16
  4. Primary completion date: Oct 31, 2025 to Jul 20, 2026
    • Study completion date: Jun 30, 2026 to Sep 12, 2026
    v15
  5. Primary completion date: Aug 15, 2023 to Oct 31, 2025v14
Show 12 earlier versionsHide 12 earlier versions
  1. Re-verified, no change to tracked fieldsv13
  2. Study sites: 45 to 44v12
  3. Study sites: 55 to 45v11
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 55 of 55 sites
    v10
  5. Primary completion date changed from estimate of Jun 27, 2023 to Aug 15, 2023
    • Study completion date: Jun 27, 2026 to Jun 30, 2026
    v9
  6. Primary completion date: May 26, 2023 to Jun 27, 2023
    • Study completion date: May 26, 2026 to Jun 27, 2026
    v8
  7. Study sites: 43 to 55v7
  8. Study sites: 36 to 43v6
  9. Study sites: 26 to 36v5
  10. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 18, 2021 to Jun 25, 2021
    • Site details revised at 26 of 26 sites
    v4
  11. Study sites: 3 to 26
    • Start date: May 26, 2021 to Jun 18, 2021
    v3
  12. Study Status, Referencesv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Takeda
222 trials monitored
See 14 trials at risk
Crohn's Disease
643 trials monitored
See 36 trials at risk
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
Trial Details
NCT Number NCT04809363
Lead Sponsor Takeda
Conditions
(from sponsor)		 Crohn's Disease
Related terms Crohn Disease
Enrollment 241 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov